According to our (Global Info Research) latest study, the global Biobanking market size was valued at US$ 3662 million in 2025 and is forecast to a readjusted size of US$ 5751 million by 2032 with a CAGR of 6.7% during review period.
Biobanking is the end-to-end infrastructure and operating system that manages biospecimens and their associated data across the full life cycle—standardized collection, processing, quality control, aliquoting, storage, traceability, and compliant access. It covers human and non-human samples (e.g., blood, tissue, cells, DNA/RNA, and other biofluids) and integrates clinical phenotypes, longitudinal follow-up, omics outputs, and metadata under a single governance and quality framework.
Multi-omics, precision medicine, and translational R&D are pushing demand for high-quality, reusable, and traceable specimens that can withstand stringent analytical and regulatory expectations. As clinical development increasingly relies on biomarker-guided stratification and companion diagnostics, biobanks are evolving from local repositories into collaborative platforms that enable cross-site studies and consistent evidence generation. Maturing global quality and best-practice frameworks further accelerate institutional adoption by formalizing competence, process control, and governance expectations. Key constraints concentrate on compliance, consistency, and operational resilience. Divergent interpretations around secondary use, broad consent, and research exemptions can complicate multi-country collaboration and data sharing; variability in pre-analytics, freeze–thaw handling, and metadata completeness can undermine reproducibility and reduce the scientific value of collections. On the operational side, ultra-low-temperature infrastructure, liquid-nitrogen safety, redundancy planning, and incident response are essential to prevent irreversible loss of specimen integrity and institutional trust. Demand is shifting from “store samples” to “deliver evidence”: biopharma seeks collections that are directly usable for biomarker discovery, patient stratification, and diagnostic development; hospitals and academia emphasize cohort building, longitudinal follow-up, and multi-center sharing; CROs and testing labs require stronger traceability and standardized data interfaces. In parallel, dynamic consent models, auditable governance, privacy-enhancing approaches, and federated collaboration patterns are gaining momentum as pathways to scale access while maintaining compliance and participant trust. The upstream stack combines consumables, cold-chain hardware, digital systems, and services. Core consumables include cryovials/cryobags, 2D-barcode labels and printing materials, racks/boxes, aliquoting tools, and stabilization buffers. Critical equipment spans ultra-low-temperature freezers, liquid-nitrogen storage, automated aliquoting and retrieval robotics, environmental monitoring and alarm sensors, backup power, and cold-chain transport tools. On the digital side, LIMS and specimen-management platforms—plus identity/access control, audit trails, and system integration—are increasingly central as biobanking converges toward automation, traceability, and compliance-ready operations.
This report is a detailed and comprehensive analysis for global Biobanking market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Biobanking market size and forecasts, in consumption value ($ Million), 2021-2032
Global Biobanking market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Biobanking market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Biobanking market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biobanking
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biobanking market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Thermo Fisher, Beckman Coulter, Panasonic, SOL Group, Promega, Merck, Greiner Bio One, Kryosphere, Precision for Medicine, Azenta, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Biobanking market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Blood
Tissue
Cells
Other
Market segment by Storage Temperature Tier
Ambient
2–8°C Refrigerated
-20°C Freezer
-80°C ULT
Other
Market segment by Research Focus
Oncology
Immunology
Infectious Disease
Public Health
Metabolic
Other
Market segment by Application
Life Sciences and Medicine
Hospitals
Research Institutions
Other
Market segment by players, this report covers
Thermo Fisher
Beckman Coulter
Panasonic
SOL Group
Promega
Merck
Greiner Bio One
Kryosphere
Precision for Medicine
Azenta
QIAGEN
Vigilant Bioservices
Lifeline Scientific
Masy BioServices
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Biobanking product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Biobanking, with revenue, gross margin, and global market share of Biobanking from 2021 to 2026.
Chapter 3, the Biobanking competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Biobanking market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biobanking.
Chapter 13, to describe Biobanking research findings and conclusion.
Summary:
Get latest Market Research Reports on Biobanking. Industry analysis & Market Report on Biobanking is a syndicated market report, published as Global Biobanking Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Biobanking market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.